ST Wandao (002082.SZ) subsidiary WP107's multiple-dose escalation clinical study of drugs has obtained FDA approval.

The Zhitong Finance and Economics APP reported that ST Wanbang (002082.SZ) announced that its wholly-owned subsidiary Wanbangde Pharmaceutical Group Co., Ltd. independently developed a new drug WP107 (oral solution of cyclosporine A) for the treatment of generalized myasthenia gravis. The drug has recently been approved by the U.S. Food and Drug Administration (FDA) for a multi-dose escalation clinical trial in healthy participants.